GelMEDIX Inc. is an early-stage ocular cell therapy company committed to improving current approaches by engineering formulations to improve cell viability, engraftment, and tissue regeneration with the aim of restoring vision.
GelMEDIX was founded after multiple years of fruitful academic collaboration between our co-founders Reza Dana (Mass. Eye And Ear, Harvard Med. School) and Nasim Annabi (UCLA).
PROPRIETARY HYDROGEL PLATFORM
Our proprietary photo-crosslinked hydrogels uniquely enable
bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies.
Our lead program is an integrated hydrogel cell therapy designed to
restore vision for macular degeneration patients with Dry AMD and geographic atrophy.
CHIEF DEVELOPMENT OFFICER
Art has over 25 years of experience in medtech product development with a focus on biomaterials and drug delivery. Most recently, he spent 10 years as the VP of R&D at Ocular Therapeutix bringing ReSure and Dextenza to commercial launch and multiple other products from concept through to clinical study.
Dr. Dana is the Chief of Cornea at Mass. Eye and Ear and Chair in Ophthalmology at Harvard Medical School. He is the founder of multiple ophthalmic focused companies with $100m+ raised to date with 15 INDs.
Dr. Ananbi is an Asst. Professor of Chemical and Bimolecular Engineering at UCLA. She is the recipient of multiple awards for young investigators from the Society for Biomaterials and the American Institute for Chemical Engineers.
SR. MANAGER CORPORATE DEVELOPMENT AND OPERATIONS
Max works at the intersection of science and business operations for GelMEDIX. He has a PhD in Medical Engineering from MIT with a research background in drug delivery.
SCIENTIST - BIOMATERIALS
Noel is an expert in biomaterials engineering and drug release. He holds a PhD in Biomedical Engineering from Brown University with a research focus on responsive hydrogel systems.
SCIENTIST - STEM CELL BIOLOGY
Alex is an expert in stem cell differentiation and neural cell biology. He holds a PhD in Neuroscience from the University of Michigan with a research focus in neuroplasticity.
Arthur is biomedical engineer with a focus on drug release with a BS in Biomedical Engineering from Drexel University.
Partners and Advisors
Michael Cima, PhD
MIT PROFESSOR, SERIAL ENTREPRENEUR
Dean Eliott, MD
DIR. EMERETIS RETINA, MASS. EYE AND EAR
Brian Ballios, MD, PhD
PHYSICIAN SCIENTIST UNIV. OF TORONTO